Skip to main content

Table 2 Adverse events in recurrent SE episodes of the total study cohort and both groups (patients with or without diabetes)

From: Does diabetes mellitus affect the safety profile of valproic acid for the treatment of status epilepticus? A retrospective cohort study

Characteristics

Recurrent SE

Group, diabetes

Group, no diabetes

p-value

Episodes

N = 74

N = 27

N = 47

 

Stop treatment with VPA

19 (26%)

6 (22%)

13 (28%)

0.606

Reason: adverse events*

6 (8%)

3 (11%)

3 (6%)

0.662

Reason: interaction of medication*

5 (7%)

1 (4%)

4 (9%)

0.647

Other reasons, no adverse events*

8 (11%)

2 (7%)

6 (13%)

0.702

Adverse events

Disturbance of consciousness*

2 (3%)

1 (4%)

1 (2%)

1.0

Thrombocytopenia*

1 (1%)

1 (4%)

0

0.365

Parkinsonism*

0

0

0

/

Elevation of liver enzymes*

1 (1%)

0

1 (2%)

1.0

Bleeding*

0

0

0

/

Others*

2 (3%)

1 (4%)

1 (2%)

1.0

  1. In another SE episode VPA was stopped due to an aggravation of a pre-existing thrombocytopenia
  2. Categorial variables were described with number and percentage. Proportions were compared using Pearson´s Chi2 test or Fisher´s exact test (*). Statistically significant values (p < 0.05) are expressed in bold
  3. SE status epilepticus; VPA valproic acid